Consolidated Entities and Acquisitions - Theravance Respiratory Company, LLC (Details) - USD ($) $ in Thousands		3 Months Ended							9 Months Ended			12 Months Ended
	Jul. 20, 2022	Sep. 30, 2022		Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022		Sep. 30, 2021	Dec. 31, 2021
Assets
Cash and cash equivalents		$ 300,789				$ 135,115			$ 300,789		$ 135,115	$ 201,525
Receivables from collaboration arrangement		65,606							65,606			110,711
Prepaid expenses		7,932							7,932			1,367
Equity and long-term investments		489,111							489,111			483,845
Total assets		1,327,712							1,327,712			926,395
Liabilities and LLC Members' Equity
Current liabilities		163,884							163,884			5,807
Total liabilities and stockholders' equity		1,327,712							1,327,712			$ 926,395
Income statements
Total revenue		67,257				97,862			265,536		284,186
Operating expenses		(219,167)				(25,315)			(86,101)		(104,601)
Other expense (income), net		28				(652)			(750)		(2,036)
Income tax expense net		57,077				20,531			63,061		65,600
Changes in fair values of equity and long-term investments		130				33,613			(67,881)		133,973
Net income (loss)		229,347		$ 21,371	$ 37,858	102,646	$ 110,846	$ 109,695	288,576		323,187
Royalty revenue from a related party
Income statements
Total revenue		62,150				97,862			260,429		284,186
Theravance Respiratory Company, LLC
CONSOLIDATED ENTITIES
Ownership interest in LLC												15.00%
Proceeds from sale of economic interest under Equity Purchase Agreement	$ 277,500
Contingent sales based milestone payment	50,000
Cash distribution	4,400
Total carrying value of investments	$ 39,400
Assets
Cash and cash equivalents												$ 50,713
Receivables from collaboration arrangement												42,492
Prepaid expenses												71
Equity and long-term investments												37,695
Total assets												130,971
Liabilities and LLC Members' Equity
Current liabilities												252
LLC members' equity												130,719
Total liabilities and stockholders' equity												$ 130,971
Income statements
Operating expenses		(5)	[1]			194			332	[2]	3,811
Income from operations		5	[1]			35,391			71,697	[2]	80,244
Other expense (income), net		0	[1]			0			10	[2]	0
Realized loss		(39,386)	[1]			0			(39,386)	[2]	0
Income tax expense net		0	[1]			0			1	[2]	0
Changes in fair values of equity and long-term investments		0	[1]			148			(8,884)	[2]	(589)
Net income (loss)		(39,381)	[1]			35,539			23,438	[2]	79,655
Theravance Respiratory Company, LLC | Royalty revenue from a related party
Income statements
Total revenue		$ 0	[1]			$ 35,585			$ 72,029	[2]	$ 84,055

[1] Three months ended September 30, 2022 represents the period from July 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.

[2] Nine months ended September 30, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.